Rossari Biotech's Q3 FY 2025-26 Quarterly Results
- 3d ago
Result Summary
- Rossari Biotech Ltd reported a 0.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 13.4%.
- Its expenses for the quarter were up by 0.3% QoQ and 14.6% YoY.
- The net profit decreased 11.1% QoQ and increased 3.4% YoY.
- The earnings per share (EPS) of Rossari Biotech Ltd stood at 5.91 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 582.19 | 587.71 | 513.28 | -0.9% | 13.4% |
Total Expenses | 540.08 | 538.50 | 471.23 | 0.3% | 14.6% |
Profit Before Tax | 42.10 | 49.20 | 42.05 | -14.4% | 0.1% |
Tax | 9.73 | 12.80 | 10.68 | -24.0% | -8.9% |
Profit After Tax | 32.77 | 36.88 | 31.70 | -11.1% | 3.4% |
Earnings Per Share | 5.91 | 6.65 | 5.72 | -11.1% | 3.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Rossari Biotech Ltd is a prominent player in the specialty chemicals industry, primarily focusing on providing solutions across various sectors, including home and personal care, performance chemicals, and textile specialty chemicals. The company is known for its innovative approach to manufacturing and supplying a diverse range of chemical products that cater to a wide array of industrial applications. While specific recent developments about the company might not be available within the provided context, Rossari Biotech is recognized for its commitment to sustainability and innovation, aligning with industry trends focusing on eco-friendly and efficient chemical solutions.
Revenue
In the third quarter of fiscal year 2026 (Q3FY26), Rossari Biotech Ltd reported a total income of ₹582.19 crores. This represents a slight decrease of 0.9% from the previous quarter (Q2FY26), where the total income was ₹587.71 crores. However, on a year-over-year basis, the company experienced a 13.4% growth in total income compared to ₹513.28 crores recorded in the third quarter of the previous fiscal year (Q3FY25). This data indicates the company's ability to maintain substantial revenue growth compared to the same period last year, despite a slight decline from the previous quarter.
Profitability
In terms of profitability, Rossari Biotech Ltd's profit before tax (PBT) for Q3FY26 stood at ₹42.10 crores, which is a 14.4% decline from the previous quarter's PBT of ₹49.20 crores. On a year-on-year comparison, the PBT remained relatively stable, showing a marginal increase of 0.1% from ₹42.05 crores in Q3FY25. The company incurred a tax expense of ₹9.73 crores in Q3FY26, which is a reduction of 24.0% from the previous quarter's tax of ₹12.80 crores and an 8.9% decrease from ₹10.68 crores in Q3FY25. Consequently, the profit after tax (PAT) for Q3FY26 amounted to ₹32.77 crores, marking an 11.1% decrease from the ₹36.88 crores in Q2FY26, but a 3.4% increase compared to ₹31.70 crores in Q3FY25.
Operating Metrics
Earnings per share (EPS) for Rossari Biotech Ltd in Q3FY26 were reported at ₹5.91, which shows an 11.1% decline from the previous quarter's EPS of ₹6.65. However, compared to the same quarter in the previous fiscal year, where the EPS was ₹5.72, there is a 3.3% increase. The operating expenses for the company in Q3FY26 totaled ₹540.08 crores, reflecting a slight increase of 0.3% from ₹538.50 crores in Q2FY26 and a 14.6% increase from ₹471.23 crores in Q3FY25. These metrics illustrate the company's operational efficiency and cost management over the periods in question, providing a quantitative insight into its financial operations.